Emory University

Andrew Taylor

Malgorzata Lipowska

Luigi G Marzilli

Jeffrey Klenc

Lory Hansen

This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes compriseTc or Re. In certain embodiments, the ligands are substituted with a fluorine, a fluorine-18(F) radioisotope, or other radionuclide.

Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers

This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes compriseTc or Re. In certain embodiments, the ligands are substituted with a fluorine, a fluorine-18 (F) radioisotope, or other radionuclide.

The present invention relates to novel metal chelates, exemplified as technetium-99m or rhenium chelates, and to the process of preparing such metal chelates from corresponding ligands. These ligands and their corresponding metal chelates are synthesized to have a cysteinylethylene (EC) structure, a monothiourea (MTU) structure, or a dithiourea (DTU) structure. The present invention further relates to a pharmaceutical composition comprising a metal chelate, for example, a .sup.99m Tc-chelate, to the use of the composition for renal imaging and examination of renal function, and to a kit for preparing such a composition prior to use.

Metal chelates as pharmaceutical imaging agents, processes of making

The present invention relates to novel metal chelates, exemplified as technetium-99m or rhenium chelates, and to the process of preparing such metal chelates from corresponding ligands. These ligands and their corresponding metal chelates are synthesized to have a cysteinylethylene (EC) structure, a thioacetamidethiourea (TATU) structure, or a dithiourea (DTU) structure. The present invention further relates to a pharmaceutical composition comprising a metal chelate, for example, a .sup.99m Tc-chelate, to the use of the composition for renal imaging and examination of renal function, and to a kit for preparing such a composition prior to use.

Growing community of inventors

Atlanta, GA, United States of America

Andrew Taylor